EMD - Emyria opens Empax Centre to target care gaps in resistant PTSD

(NewsDirect)

Emyria Ltd (ASX:EMD) CEO Michael Winlo sits down with Proactive’sJonathan Jackson to discuss significant advancements in thecompany's mental health initiatives. Emyria recently opened theEmpax Centre, a cutting-edge facility aimed at enhancing mental healthtreatments, including MDMA-assisted therapy for PTSD. Emyria’sambitious vision is showcased by this centre, targeting care gaps inresistant PTSD, with sights set on operational profitability andglobal expansion. Winlo discusses how the technology employed at theEmpax Centre enhances patient care as well as Emyria’s plans tobroaden its therapeutic offerings. Significant progress has also beenmade with the expansion of Emyria’s authorised prescriber team. Theaddition of a second psychiatrist as an authorised prescriberunderlines Emyria’s commitment to advancing mental health care,aligning with its expansion efforts. Emyria is also collaborating withcharity Reach Wellness and this partnership signifies a strategic steptowards validating Emyria’s MDMA-assisted therapy model, aiming toimprove PTSD treatment for first responders. This collaboration,backed by significant fundraising, is pivotal for demonstrating themodel’s safety, effectiveness and scalability.

ContactDetails

Proactive Investors

JonathanJackson

+61 413 713 744

jonathan@proactiveinvestors.com

Copyright (c) 2024 TheNewswire - All rights reserved.